Literatur
-
1
Rubin L J.
Current concepts: primary pulmonary hypertension.
N Engl J Med.
1997;
336
111-117
-
2
Olschewski H, Olschewski A, Rose F. et al .
Physiologic basis for the treatment of pulmonary hypertension.
J Lab Clin Med.
2001;
138
287-297
-
3
Olschewski H, Rose F. et al .
Cellular pathophysiology and therapy of pulmonary hypertension.
J Lab Clin Med.
2001;
138
367-377
-
4
Deng Z, Morse J H, Slager S L. et al .
Familial primary pulmonal hypertension is caused by mutations in the bone morphogenetic proteine receptor-II gene.
Am J Hum Genet.
2000;
67
737-744
-
5
Machado R D, Pauciulo M W, Thomson J R. et al .
BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.
Am J Hum Genet.
2001;
68
92-102
-
6
Olschewski H, Ghofrani A, Wiedemann R. et al .
Pulmonaler Hochdruck.
Internist.
2002;
43
1498-1509
-
7
Sitbon O, Humbert M, Jagot J L. et al .
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calciumchannel blockers in primary pulmonary hypertension.
Eur Respir J.
1998;
12
265-270
-
8
Higenbottam T, Wheeldon D, Wells F. et al .
Long-term treatment of primary pulmonary hypertension with continous intravenous epoprostenol (prostacyclin).
Lancet.
1984;
1
1046-1047
-
9
Hoeper M M, Olschewski H, Ghofrani H A. et al .
A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group.
J Am Coll Cardiol.
2000;
35
176-182
-
10
Channick R N, Simmonneau G, Sitbon O. et al .
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension.
Lancet.
2001;
358
1119-1123
Mirko Sicksch
Herz- und Diabeteszentrum NRW, Kardiologische Intensivstation
Georgstrasse 11
32545 Bad Oeynhausen
eMail: m.sicksch@teleos-web.de
